Experiment on enhancing antitumor effect of intravenous epirubicin hydrochloride by acoustic cavitation in situ combined with phospholipid-based microbubbles.
OBJECTIVE
An in vivo study on enhancing antitumor effect of intravenous epirubicin hydrochloride (EPI) by acoustic cavitation in situ combined with phospholipid-based microbubbles (PMB) was reported.


METHODS
Five-week-old male nude mice were used, and HCT-116 cells were s.c. (subcutaneous injection) inoculated in axilla of these mice. Five groups were designed and five consecutive treatments were applied to investigate the tumor growth, body weight growth, and normal organ growth.


RESULTS
Inhibition effects on tumor growth were observed in all groups treated by EPI. However, the potency of tumor growth retardation caused by EPI depended on the application of PMB and US in situ. An effective retardation on tumor growth and improved mice survival status were observed when intravenous EPI combined with sonicated PMB in situ. Short-term lingering sensitive period for chemotherapeutic drugs after acoustic cavitation was also observed in experiment under asynchronous administration of EPI and sonicated PMB.


CONCLUSIONS
Intravenous EPI combined with PMB-mediated cavitation in situ might provide a potential application for US-mediated chemotherapy.
Lu
Cui-Tao
CT
Pharmacy School, Wenzhou Medical College, Zhejiang Province, China.
Zhao
Ying-Zheng
YZ
Wu
Yan
Y
Tian
Xin-Qiao
XQ
Li
Wen-Feng
WF
Huang
Pin-Tong
PT
Li
Xiao-Kun
XK
Sun
Chang-Zheng
CZ
Zhang
Lu
L
D000818:Animals; D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage* / Q000627:therapeutic use; D016503:Drug Delivery Systems; D015251:Epirubicin / Q000008:administration & dosage* / Q000627:therapeutic use; D045325:HCT116 Cells; D006801:Humans; D015552:Injections, Intralesional; D007275:Injections, Intravenous; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D008819:Mice, Nude; D045423:Microbubbles / Q000627:therapeutic use*; D010743:Phospholipids / Q000008:administration & dosage* / Q000627:therapeutic use; D011897:Random Allocation; D013010:Sonication; D016019:Survival Analysis; D013997:Time Factors; D047368:Tumor Burden / Q000187:drug effects; D023041:Xenograft Model Antitumor Assays
D000903:Antibiotics, Antineoplastic; D010743:Phospholipids; D015251:Epirubicin